Fludarabine and cyclophosphamide provides a nonmyeloablative alternative conditioning regimen with low transplant-related mortality and control of high risk disease

by Pamela Paplham, Theresa Hahn, Karen Dubel, Patricia Lipka, Philip L. McCarthy
Published 2014-01-01

Future Directions in Maintenance Therapy in Multiple Myeloma

by Sarah A. Holstein, Vera J. Suman, Jens Hillengass, Philip L. McCarthy
Published 2021-05-01

Common genetic variants are associated with accelerated bone mineral density loss after hematopoietic cell transplantation.

by Song Yao, Lara E Sucheston, Shannon L Smiley, Warren Davis, Jeffrey M Conroy, Norma J Nowak, Christine B Ambrosone, Philip L McCarthy, Theresa Hahn
Published 2011-01-01

Serine protease inhibitor 6 protects alloreactive T cells from Granzyme B-mediated mitochondrial damage without affecting graft-versus-tumor effect

by Wei Du, Hemn Mohammadpour, Rachel E. O'Neill, Sandeep Kumar, Chuan Chen, Michelle Qiu, Lin Mei, Jingxin Qiu, Philip L. McCarthy, Kelvin P. Lee, Xuefang Cao
Published 2018-03-01

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events

by Frederick L Locke, Elizabeth J Shpall, Jorg Dietrich, Daniel W Lee, Matthew J Frigault, Terry J Fry, Sara Alexander, Jennifer N Brudno, Colleen Callahan, Marco L Davila, Claudia Diamonte, Julie C Fitzgerald, Jennifer L Holter-Chakrabarty, Krishna V Komanduri, Shannon L Maude, Philip L McCarthy, Elena Mead, David T Teachey, Cameron J Turtle, Tom Whitehead
Published 2020-07-01